SHR 3792
Alternative Names: SHR-3792Latest Information Update: 15 Apr 2025
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral) before April 2025
- 02 Apr 2025 Suzhou Suncadia Biopharmaceuticals plans a phase I trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (Parenteral, Injection) in April 2025 (NCT06907628)